Literature DB >> 14654600

A comparison of on-site and off-site patent ductus arteriosus ligation in premature infants.

Douglas S Gould1, Lisa M Montenegro, J William Gaynor, Suzanne P Lacy, Richard Ittenbach, Paul Stephens, James M Steven, Thomas L Spray, Susan C Nicolson.   

Abstract

INTRODUCTION: Persistent patent ductus arteriosus (PDA) often produces hemodynamic and respiratory derangement necessitating use of inotropic drugs and escalating ventilatory support in premature infants. When medical therapy fails, surgical ligation is indicated. Because of the risks of transferring unstable neonates to the operating room, ductal ligation is routinely performed at the neonatal intensive care unit (NICU) bedside. Some patients, however, require transfer from hospitals without pediatric cardiac surgical teams. In an attempt to eliminate the risks associated with transfer, a surgical team from our institution offered to perform duct ligation in the NICUs of referring institutions. This experienced team consisted of a pediatric cardiac attending anesthesiologist and certified registered nurse anesthetist, cardiac operating room nurses, an attending cardiothoracic surgeon, and a cardiothoracic surgery fellow. We retrospectively reviewed our experience.
METHODS: After approval from the Committee for the Protection of Human Subjects, the charts of premature neonates who underwent PDA ligation in the NICU at the Children's Hospital of Philadelphia NICU or in a network NICU between January 1996 and April 2002 were reviewed. Data abstracted included institution, gender, gestational age, birth weight, weight at surgery, and number of courses of indomethacin. Mean arterial blood pressure and use of inotropic drugs and ventilatory parameters (fraction of inspired oxygen, peak inspiratory pressure) were recorded at the time of surgery and 96 hours postoperatively. Perioperative complications were recorded.
RESULTS: Seventy-two patients met the criteria for inclusion. PDA ligation was performed in the Children's Hospital of Philadelphia NICU in 38 of 72 patients, 53% (group 1). The remainder, 34 of 72 (47%) underwent PDA ligation in the NICU at 1 of 6 referring institutions (group 2). There were no significant differences between groups with respect to demographics, number of courses of indomethacin, or use of inotropic drugs or ventilatory support. The incidence of perioperative complications did not differ between groups: 3 in group 1 (bleeding, chylothorax, and pleural effusion) and 3 in group 2 (pneumothorax [3]). There were no anesthetic-related complications. Seven patients died (4 in group 1 and 3 in group 2), none within 96 hours of surgery and none secondary to the procedure. DISCUSSION: The data demonstrate that an experienced team can perform PDA ligation safely in NICUs of hospitals without on-site pediatric cardiac surgical capabilities in critically ill neonates without incurring the risks inherent in patient transport. Most importantly, patient care is continued by the neonatology team most familiar with the infant's medical and social history, and the patient's family is minimally inconvenienced.

Entities:  

Mesh:

Year:  2003        PMID: 14654600     DOI: 10.1542/peds.112.6.1298

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  10 in total

1.  Scope and feasibility of operating on the neonatal intensive care unit: 312 cases in 10 years.

Authors:  N J Hall; M P Stanton; L J Kitteringham; R A Wheeler; D M Griffiths; M Drewett; D M Burge
Journal:  Pediatr Surg Int       Date:  2012-08-21       Impact factor: 1.827

2.  Patent ductus arteriosus in premature infants: to treat or not to treat?

Authors:  M A Mohamed; M El-Dib; S Alqahtani; K Alyami; A N Ibrahim; H Aly
Journal:  J Perinatol       Date:  2017-02-16       Impact factor: 2.521

3.  Vocal fold paralysis following surgical ductal closure in extremely low birth weight infants: a case series of feeding and respiratory complications.

Authors:  W F Malcolm; C Hornik; A Evans; P B Smith; C M Cotten
Journal:  J Perinatol       Date:  2008-11       Impact factor: 2.521

4.  The impact of a dedicated patent ductus arteriosus ligation team on neonatal health-care outcomes.

Authors:  M H F Resende; K More; D Nicholls; J Ting; A Jain; P J McNamara
Journal:  J Perinatol       Date:  2016-01-14       Impact factor: 2.521

Review 5.  Bedside neonatal intensive care unit surgery- myth or reality!

Authors:  Shandip Kumar Sinha; Sujoy Neogi
Journal:  J Neonatal Surg       Date:  2013-04-01

6.  Neonatal Patent Ductus Arteriosus Ligation Operations Performed by Adult Cardiac Surgeons.

Authors:  Yoon Sang Chung; Dai Yun Cho; Hyun Kang; Na Mi Lee; Joonhwa Hong
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2017-08-05

7.  A comparison of postoperative outcomes with PDA ligation in the OR versus the NICU: a retrospective cohort study on the risks of transport.

Authors:  Lisa K Lee; Michelle Y Woodfin; Marissa G Vadi; Tristan R Grogan; Phillip J Ross; Richard L Applegate; Marc Iravani
Journal:  BMC Anesthesiol       Date:  2018-12-22       Impact factor: 2.217

8.  Anesthesia protocols for "bedside" preterm patent ductus arteriosus ligation: A single-institutional experience.

Authors:  Reena Khantwal Joshi; Neeraj Aggarwal; Mridul Agarwal; Raja Joshi
Journal:  Ann Pediatr Cardiol       Date:  2021-08-26

9.  An Update on Patent Ductus Arteriosus and What is Coming Next.

Authors:  Ömer Erdeve; Emel Okulu; Yogen Singh; Richard Sindelar; Mehmet Yekta Oncel; Gianluca Terrin; Giovanni Boscarino; Ali Bülbül; Hannes Sallmon; Begüm Atasay; Fahri Ovalı; Ronald I Clyman
Journal:  Turk Arch Pediatr       Date:  2022-03

10.  Outcome following surgical closure of patent ductus arteriosus in very low birth weight infants in neonatal intensive care unit.

Authors:  Ga Yeun Lee; Young Bae Sohn; Myo Jing Kim; Ga Won Jeon; Jae Won Shim; Yun Sil Chang; June Huh; I-Seok Kang; Ji-Hyuk Yang; Tae-Gook Jun; Pyo Won Park; Won Soon Park; Heung Jae Lee
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.